Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ishares Msci Italy ETF (EWI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ishares Msci Italy ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.65 (market cap $29.60B), while Ishares Msci Italy ETF trades at $63.15. The key difference: Ishares Msci Italy ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWI | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $63.35 |
52-Week Low | $205.48 | $50.31 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
EWI trades at $63.165, showing minimal daily movement with a slight decline of 0.01%. The technical outlook is bullish based on moving averages, though oscillators signal neutrality with RSI readings above 80 indicating potential overbought conditions. Recent news highlights Italy's market strength with EWI hitting a 52-week high in June 2026, driven by improving industrial data and recovery narrative. A dividend of $1.17 is scheduled for June 2026, providing income appeal.
The stock benefits from positive European market sentiment and Italy's economic recovery, but faces risks from ECB rate policy and energy price volatility. Technical indicators suggest near-term consolidation may be needed given overbought signals. Long-term prospects appear favorable if Italy's economic momentum continues, though investors should monitor ECB decisions and energy market developments closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →
